Lambda interferons (IFNLs) have potent antiviral activity against HCV, and polymorphisms within the IFNL gene cluster near the IFNL3 gene strongly predict spontaneous- and treatment-related HCV infection outcomes. The mechanism(s) linking IFNL polymorphisms and HCV control is currently elusive.
Methods
IFNL induction was studied in primary human hepatocytes (PHH) from 18 human donors, peripheral blood mononuclear cells (PBMCs) from 18 human donors, multiple cell lines and induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-hepatocytes) from 7 human donors. After stimulation with intracellular RNA and infectious HCV, quantitative PCR (qPCR) primers and probes were designed to distinguish and quantify closely related IFNL messenger (m)RNAs from IFNL1, IFNL2 and IFNL3.
Results
PHH demonstrated the most potent induction of IFNLs, although had lower pre-stimulation levels compared to PBMCs, monocytes and cell lines. PHH stimulation with cytoplasmic poly I:C induced >1,000-fold expression of IFNL1, IFNL2 and IFNL3. PHH from donors who were homozygous for the favourable IFNL3 allele (IFNL3-CC) had higher IFNL3 induction compared to PHH from IFNL3-TT donors (P=0.03). Baseline IFNL mRNA expression and induction was also tested in iPSC-hepatocytes: iPSC-hepatocytes had significantly higher baseline expression of IFNLs compared to PHH (P<0.0001), and IFNL3 induction was marginally different in iPSC-hepatocytes by IFNL genotype (P=0.07).
Conclusions
Hepatocytes express IFNLs when stimulated by a synthetic viral RNA that signals the cell through the cytoplasm. IFNL induction may be greater in persons with the favourable IFNL3 allele. These data provide insight into the strong linkage between IFNL3 genetics and control of HCV infection.
References
1.
HanafahK.M., GroegerJ., FlaxmanA.D., WiersmaS.T.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence.Hepatology2013; 57: 10.
2.
VillanoS.A., VlahovD., NelsonK.E., CohnS., ThomasD.L.Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.Hepatology1999; 29: 908–914.
3.
ThomasD.L., AstemborskiJ., RaiR.M.The natural history of hepatitis C virus infection: host, viral, and environmental factors.JAMA2000; 284: 450–456.
4.
BalagopalA., ThomasD.L., ThioC.L.IL28B and the control of hepatitis C virus infection.Gastroenterology2010; 139: 1865–1876.
5.
ThomasD.L., ThioC.L., MartinM.P.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.Nature2009; 461: 798–801.
6.
RauchA., KutalikZ., DescombesP.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.Gastroenterology2010; 138: 1338–1345.
7.
DuggalP., ThioC.L., WojcikG.L.Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.Ann Intern Med2013; 158: 235–245.
8.
GeD., FellayJ., ThompsonA.J.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Nature2009; 461: 399–401.
9.
Prokunina-OlssonL., MuchmoreB., TangW.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.Nat Genet2013; 45: 164–171.
10.
BibertS., RogerT., CalandraT.IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.J Exp Med2013; 210: 1109–1116.
11.
DellgrenC., GadH.H., HammingO.J., MelchjorsenJ., HartmannR.Human interferon-lambda3 is a potent member of the type III interferon family.Genes Immun2009; 10: 125–131.
12.
KurbanovF., Abdel-HamidM., LatanichR.Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.J Infect Dis2011; 204: 1391–1394.
13.
SuppiahV., MoldovanM., AhlenstielG.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Nat Genet2009; 41: 1100–1104.
14.
TanakaY., NishidaN., SugiyamaM.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet2009; 41: 1105–1109.
15.
KotenkoS.V., GallagherG., BaurinV.V.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.Nat Immunol2003; 4: 69–77.
16.
SheppardP., KindsvogelW., XuW.IL-28, IL-29 and their class II cytokine receptor IL-28R.Nat Immunol2003; 4: 63–68.
17.
HondaM., SakaiA., YamashitaT.Hepatic interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C.Gastroenterology2010; 139: 499–509.
18.
UrbanT.J., ThompsonA.J., BradrickS.S.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.Hepatology2010; 52: 1888–1896.
19.
KumarR., SinghS.K., KoshkinA.A., RajwanshiV.K., MeldgaardM., WengelJ.The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2′-thio-LNA.Bioorg Med Chem Lett1998; 8: 2219–2222.
20.
PfafflM.W.A new mathematical model for relative quantification in real-time RT-PCR.Nucleic Acids Res2001; 29: e45.
21.
LiuH., YeZ., KimY., SharkisS., JangY.Y.Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes.Hepatology2010; 51: 1810–1819.
22.
ChoiS.M., LiuH., ChaudhariP.Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells.Blood2011; 118: 1801–1805.
23.
LiuH., KimY., SharkisS., MarchionniL., JangY.Y.In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins.Sci Transl Med2011; 3: 82ra39.
24.
GitlinL., BarchetW., GilfillanS.Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidy lic acid and encephalomyocarditis picornavirus.Proc Natl Acad Sci U S A2006; 103: 8459–8464.
25.
KatoH., SatoS., YoneyamaM.Cell type-specific involvement of RIG-I in antiviral response.Immunity2005; 23: 19–28.
26.
WuX., RobothamJ.M., LeeE.Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation.PLoS Pathog2012; 8: e1002617.
27.
ThompsonA.J., MuirA.J., SulkowskiM.S.Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.Gastroenterology2010; 139: 120–129.
28.
HsuC.S., HsuS.J., ChenH.C.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.Proc Natl Acad Sci U S A2011; 108: 3719–3724.
29.
HowellC.D., GordenA., RyanK.A.Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.J Hepatol2012; 56: 557–563.
30.
ChuT.W., KulkarniR., GaneE.J.Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.Gastroenterology2012; 142: 790–795.
31.
NaggieS., OsinusiA., KatsounasA.Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.Hepatology2012; 56: 444–454.
32.
NeumannA.U., LamN.P., DahariH.Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.Science1998; 282: 103–107.
33.
ThomasE., GonzalezV.D., LiQ.HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.Gastroenterology2012; 142: 978–988.
34.
Sarasin-FilipowiczM., OakeleyE.J., DuongF.H.Interferon signaling and treatment outcome in chronic hepatitis C.Proc Natl Acad Sci U S A2008; 105: 7034–7039.
35.
MartinM.P., QiY., GoedertJ.J.IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.J Infect Dis2010; 202: 1749–1753.
36.
TakahashiK., AsabeS., WielandS.Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection.Proc Natl Acad Sci U S A2010; 107: 7431–7436.
